What is the role of the D3 receptor in addiction? A mini review of PET studies with [(11)C]-(+)-PHNO

Progress in Neuro-psychopharmacology & Biological Psychiatry
Doris E PayerIsabelle Boileau


The chronic use of drugs, including psychostimulants such as cocaine and amphetamine, has been associated with low D2/3 dopamine receptor availability, which in turn has been linked to poor clinical outcome. In contrast, recent studies focused on the D3 receptor (a member of the D2-like receptor family) suggest that chronic exposure to stimulant drugs can up-regulate this receptor subtype, which, in preclinical models, is linked to dopamine system sensitization - a process hypothesized to contribute to relapse in addiction. In this mini review we present recent human data suggesting that the D3 receptor may contribute to core features of addiction, and discuss the usefulness of the PET imaging probe [(11)C]-(+)-PHNO in investigating this question.


Apr 5, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Anne-Noël Samaha, Stéphane Potvin
Jan 22, 2015·The International Journal of Neuropsychopharmacology·Michael E BallardEdythe D London
Jun 28, 2016·Pharmacology & Therapeutics·Gian Marco LeggioFilippo Drago
Jul 22, 2014·Journal of Neurochemistry·Claudia Rangel-BarajasRobert R Luedtke
Jun 12, 2019·Clinical and Experimental Reproductive Medicine·Sirin Bakti DemirayUgur Sezerman
Nov 28, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Esmaeil MansouriIsabelle Boileau
Feb 3, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Doris E PayerIsabelle Boileau
Jan 27, 2015·Addiction Biology·Dolores Vazquez-SanromanMarta Miquel
Nov 19, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Anna CastriotoPaul Krack
Sep 15, 2018·Folia Parasitologica·Andrew N BerrettDawson W Hedges
Sep 15, 2018·Molecular Psychiatry·Luke ClarkMartin Zack
Dec 29, 2015·Journal of Labelled Compounds & Radiopharmaceuticals·Natascha NebelOlaf Prante
Oct 3, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Patrick D WorhunskyMarc N Potenza


Sep 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D LévesqueP Sokoloff
Sep 1, 1987·The American Journal of Psychiatry·H R Lesieur, S B Blume
Sep 1, 1993·Brain Research. Brain Research Reviews·T E Robinson, K C Berridge
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·R BordetJ C Schwartz
May 1, 1997·Brain Research. Molecular Brain Research·D M SegalD C Mash
Jul 23, 1999·Annals of the New York Academy of Sciences·D C Mash, J K Staley
Jul 9, 2002·The European Journal of Neuroscience·B Le FollP Sokoloff
Mar 15, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laurent P LacroixChristian A Heidbreder
Mar 26, 2003·Brain Research. Molecular Brain Research·Rudolph SpanglerSarah F Leibowitz
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michela AndreoliChristian A Heidbreder
Apr 22, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Janet L NeisewanderJeffrey N Joyce
Feb 12, 2005·Behavioural Neurology·Matthias BrandHans J Markowitsch
Jun 21, 2005·Neuropharmacology·B Le FollP Sokoloff
Oct 6, 2005·Psychopharmacology·B Le Foll, Steven R Goldberg
Dec 24, 2005·Biological Psychiatry·Matthäus WilleitAlan A Wilson
Apr 15, 2006·CNS & Neurological Disorders Drug Targets·P SokoloffC Gross
Jul 21, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neil M Richtand
Nov 2, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Valentina VengelieneRainer Spanagel
Aug 11, 2007·Neuropharmacology·Paul S FrankelStephen J Kish
Jul 12, 2008·Neuropharmacology·N D VolkowF Telang
Aug 5, 2008·Neuropharmacology·Peter W KalivasHaowei Shen
Sep 17, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Florence Loiseau, Mark J Millan
Mar 6, 2010·Annals of the New York Academy of Sciences·Christian A Heidbreder, Amy H Newman
Jul 13, 2011·The International Journal of Neuropsychopharmacology·Pradeep J NathanEdward T Bullmore
Jul 19, 2011·Trends in Neurosciences·Charles L PickensYavin Shaham
Sep 1, 2011·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Paul ShotboltEugenii A Rabiner

Related Concepts

Central Nervous System Stimulant [EPC]
Adrenal Cortex Diseases
Central Nervous System Stimulants
Globus Pallidus
Dopamine D3 receptor
Positron-Emission Tomography
Pre-Clinical Model

Related Feeds


This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.